查看文章

In search of suitable therapy for the management of Alzheimer’s disease, this study was designed to evaluate metal complexes against its biochemical targets. Zinc metal carboxylates (AAZ1–AAZ6) were evaluated against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The antioxidant in combination with anticholinesterase activity can be considered as an important target in the management of Alzheimer’s disease. Therefore, these compounds were also screened for ABTS and DPPH free radical scavenging activity. In AChE inhibition assay, we noticed encouraging IC₅₀ values of 33.07 and 59.52 µM for compounds AAZ5 and AAZ3, respectively. However, when we tested BChE activity, we observed an outstanding IC₅₀ of 0.056 µM for compound AAZ6. Amazingly all of our compounds (AAZ1–AAZ6) were proved to be strong antioxidants which actively supplement the anti-Alzheimer’s activity …